• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
    • Scientific Presentations
  • Investors
    • Overview
    • News
    • Analyses
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Board and Management
    • The Share
    • Financial Reports
      • Financial Reports - English
      • Financial Reports – Swedish
      • Financial Calendar
    • Corporate Governance
    • General Meetings
    • IR Contact
  • Career
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
    • Scientific Presentations
  • Investors
    • Overview
    • News
    • Analyses
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Board and Management
    • The Share
    • Financial Reports
      • Financial Reports - English
      • Financial Reports – Swedish
      • Financial Calendar
    • Corporate Governance
    • General Meetings
    • IR Contact
  • Career
  • Contact
Home / Investors
  • Overview
  • News
  • Analyses
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • Board and Management
  • The Share
  • Financial Reports
    • Financial Reports - English
    • Financial Reports – Swedish
    • Financial Calendar
  • Corporate Governance
  • General Meetings
  • IR Contact

Investor Relations

Welcome to Alzinova AB’s IR pages.

Alzinova AB is a company specializing in the treatment of Alzheimer’s disease – one of our major health scourges, without effective treatment options.

Latest press releases

/investors/press-releases/press
View all

Latest news

  • 2025-10-07 Alzinova featured in Japanese media
  • 2025-09-30 Our CEO interviewed by Alzheimerfonden
View all

Latest financial reports

View all
  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB, Gemenskapens gata 9,  SE-431 53 Mölndal
info@alzinova.com

Follow us on

follow us on linkedin